Driscoll Christopher B, Tonne Jason M, El Khatib Moustafa, Cattaneo Roberto, Ikeda Yasuhiro, Devaux Patricia
Department of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.
Stem Cell Res Ther. 2015 Mar 26;6(1):48. doi: 10.1186/s13287-015-0035-z.
Advances in the field of stem cells have led to novel avenues for generating induced pluripotent stem cells (iPSCs) from differentiated somatic cells. iPSCs are typically obtained by the introduction of four factors--OCT4, SOX2, KLF4, and cMYC--via integrating vectors. Here, we report the feasibility of a novel reprogramming process based on vectors derived from the non-integrating vaccine strain of measles virus (MV).
We produced a one-cycle MV vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. This vector was further engineered to encode for OCT4 in an additional transcription unit.
After verification of OCT4 expression, we assessed the ability of iPSC reprogramming. The reprogramming vector cocktail with the OCT4-expressing MV vector and SOX2-, KLF4-, and cMYC-expressing lentiviral vectors efficiently transduced human skin fibroblasts and formed iPSC colonies. Reverse transcription-polymerase chain reaction and immunostaining confirmed induction of endogenous pluripotency-associated marker genes, such as SSEA-4, TRA-1-60, and Nanog. Pluripotency of derived clones was confirmed by spontaneous differentiation into three germ layers, teratoma formation, and guided differentiation into beating cardiomyocytes.
MV vectors can induce efficient nuclear reprogramming. Given the excellent safety record of MV vaccines and the translational capabilities recently developed to produce MV-based vectors now used for cancer clinical trials, our MV vector system provides an RNA-based, non-integrating gene transfer platform for nuclear reprogramming that is amenable for immediate clinical translation.
干细胞领域的进展为从分化的体细胞中生成诱导多能干细胞(iPSC)开辟了新途径。iPSC通常通过整合载体导入四种因子——OCT4、SOX2、KLF4和cMYC来获得。在此,我们报告了一种基于源自麻疹病毒(MV)非整合疫苗株的载体的新型重编程过程的可行性。
我们通过将病毒附着蛋白基因替换为绿色荧光蛋白(GFP)基因来制备单周期MV载体。该载体进一步经过工程改造,在另一个转录单元中编码OCT4。
在验证OCT4表达后,我们评估了iPSC重编程的能力。含有表达OCT4的MV载体以及表达SOX2、KLF4和cMYC的慢病毒载体的重编程载体混合物有效地转导了人皮肤成纤维细胞并形成了iPSC集落。逆转录-聚合酶链反应和免疫染色证实了内源性多能性相关标记基因的诱导,如SSEA-4、TRA-1-60和Nanog。通过自发分化为三个胚层、形成畸胎瘤以及定向分化为跳动的心肌细胞,证实了所衍生克隆的多能性。
MV载体可诱导高效的核重编程。鉴于MV疫苗出色的安全记录以及最近开发的用于生产基于MV的载体(现用于癌症临床试验)的转化能力,我们的MV载体系统为核重编程提供了一个基于RNA的、非整合的基因转移平台,适合立即进行临床转化。